<SEC-DOCUMENT>0001193125-16-760778.txt : 20161107
<SEC-HEADER>0001193125-16-760778.hdr.sgml : 20161107
<ACCEPTANCE-DATETIME>20161107060633
ACCESSION NUMBER:		0001193125-16-760778
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161106
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161107
DATE AS OF CHANGE:		20161107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COOPER COMPANIES INC
		CENTRAL INDEX KEY:			0000711404
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				942657368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08597
		FILM NUMBER:		161976463

	BUSINESS ADDRESS:	
		STREET 1:		6140 STONERIDGE MALL RD
		STREET 2:		STE 590
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588
		BUSINESS PHONE:		9254603600

	MAIL ADDRESS:	
		STREET 1:		6140 STONERIDGE MALL ROAD
		STREET 2:		SUITE 590
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COOPERVISION INC
		DATE OF NAME CHANGE:	19870701
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d254891d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;7, 2016 (November 6, 2016) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THE COOPER COMPANIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>1-8597</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2657368</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(925) 460-3600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, 2016, The Cooper Companies, Inc. (the &#147;Company&#148;) issued a press release announcing that it has acquired Wallace, the in-vitro
fertilization segment of Smiths Medical International, Ltd, a division of Smiths Group plc, for a purchase price of approximately $168&nbsp;million, subject to customary closing adjustments. A copy of the press release is attached as
Exhibit&nbsp;99.1 hereto and is incorporated herein by reference. Internet addresses in the press release is for information purposes only and are not intended to be hyperlinks to other Company information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated November 6, 2016, of The Cooper Companies, Inc.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE COOPER COMPANIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tina Maloney</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tina Maloney</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Controller</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting
Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;7, 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated November 6, 2016, of The Cooper Companies, Inc.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d254891dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g254891g1104152014616.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g254891g11v97.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6140 Stoneridge Mall Road</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Suite 590</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Pleasanton, CA 94588</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">925-460-3663</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>www.coopercos.com</U></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NEWS RELEASE</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>CONTACT:</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Kim Duncan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Vice
President, Investor Relations</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><U>ir@cooperco.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COOPER COMPANIES ACQUIRES WALLACE FROM SMITHS MEDICAL </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASANTON, Calif., November 6, 2016 </B>&#150; The Cooper Companies, Inc. (NYSE: COO) today announced that CooperSurgical has acquired Wallace, the
in-vitro fertilization (IVF) segment of Smiths Medical, a division of Smiths Group plc, for a purchase price of approximately $168 million subject to customary closing adjustments. Wallace reported sales of approximately $29 million in the last
twelve months. Excluding non-recurring items and deal-related amortization, the transaction is expected to be approximately $0.10 accretive to earnings per share in fiscal 2017.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the transaction, Robert S. Weiss, Cooper&#146;s president and chief executive officer said, &#147;This acquisition is a great strategic fit with
our existing IVF portfolio as Wallace brings the gold standard of embryo transfer catheters along with several other premier products such as oocyte retrieval needles. The addition of these products further strengthens our IVF portfolio which is
sold into fertility clinics worldwide.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Cooper Companies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cooper Companies, Inc. (&#147;Cooper&#148;) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A
Quality of Life Company&#153; with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a
wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women&#146;s
health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has approximately 10,000 employees with products sold in over 100 countries. For more information, please visit <U>www.coopercos.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CooperSurgical </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more than 25 years, CooperSurgical has been a leader in manufacturing and marketing a wide range of trusted and innovative brands that have assisted
clinicians in advancing the standard of health care for women worldwide. Through an aggressive growth and diversification strategy, CooperSurgical has evolved its portfolio to include key products and services for women&#146;s health, fertility and
genetic testing.&nbsp;Our global in-vitro fertilization (IVF) segment, ORIGIO, and our groundbreaking offering from the pioneers of genetic testing, Recombine/Reprogenetics/Genesis Genetics, complement our dynamic women&#146;s health care offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CooperSurgical, Inc. is a wholly owned subsidiary of The Cooper Companies (NYSE: COO) and is headquartered in Trumbull, CT. Through the delivery of
insightful technologies and products to health care providers, we envision a world with healthier babies, individuals, and families.&nbsp;More information can be found at <U>www.coopersurgical.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
&#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are
other than statements of historical fact, including our 2016 Guidance and all statements regarding the acquisition of Smiths Medical&#146;s Wallace including Wallace&#146;s financial position, market position, product development and business
strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and Wallace&#146;s future expenses, sales and earnings per share are forward
looking.&nbsp;In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any
acquisition are forward-looking.&nbsp;To identify these statements look for words like &#147;believes,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;seeks,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;estimates&#148; or &#147;anticipates&#148; and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and
uncertainties.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking
statements are: adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries that could adversely affect our global markets,
including the adverse economic impact and related uncertainty caused by the United Kingdom&#146;s election to withdraw from the European Union; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the
value of foreign currencies that would decrease our revenues and earnings; acquisition-related adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of the Wallace acquisition or other
acquisitions, integration delays or costs and the requirement to record </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained
or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available
financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); Our indebtedness could adversely affect our financial health, prevent us from fulfilling our debt obligations or limit
our ability to borrow additional funds; a major disruption in the operations of our manufacturing, research and development or distribution facilities, due to technological problems, including any related to our information systems maintenance,
enhancements, or new system deployments and integrations, integration of acquisitions, natural disasters, excess or constrained manufacturing capacity, or other causes; disruptions in supplies of raw materials, particularly components used to
manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing tax laws, regulations and enforcement guidance, which affect the medical device and healthcare industries generally; compliance
costs and potential liability in connection with U.S. and foreign healthcare regulations and federal and state laws pertaining to privacy and security of health information, including product recalls, warning letters, and data security breaches;
legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement or other litigation; changes in tax laws or their interpretation and
changes in statutory tax rates; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies; reduced sales, loss of customers and costs and expenses related to recalls;
failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third party payors for our products and services; the
requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; the success of&nbsp;our research and development activities and other start-up projects; dilution to earnings
per share from acquisitions or issuing stock; changes in accounting principles or estimates; environmental risks; and other events described in our Securities and Exchange Commission filings, including the &#147;Business&#148; and &#147;Risk
Factors&#148; sections in the Company&#146;s Annual Report on Form 10-K for the fiscal year ended October 31, 2015, as such Risk Factors may be updated in quarterly filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required
by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COO-G </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g254891g1104152014616.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g254891g1104152014616.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* $H# 2(  A$! Q$!_\0
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1R1@$'CT^@K0HH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g254891g11v97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g254891g11v97.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)(&+(I!*%E3< : .R^%-K:17.L3:7KEC?6#F,-;V%H\,$,F#RNYB,D8SCT%
M'I= !0 4 % !0 4 % !0 4 % !0 4 % !0!\N?%SQS?^-_%8\,:(7ETZ"80Q
MQ1?\O,V<9]P#P/S[T >D^"OA=X<^'FB_VYXG>UFU"-=\L\^#%;^R ]3[]2>E
M %/5OVC/#MG<F+3=,O+]%./-)$2GZ9R?S H M:!^T#X6U>X%KJEM/I9<[0\N
M)(N?4CD?B,4 =YH7A;0=)U6\UO188XO[3C0R" CRGQDAE X&=W;@T :FIZE8
M:+ITU_J-S%:VD(W/)(< ?_7H \DU7]HSP[;7#1:=I-Y?1]#(Q$2M] <G\P*
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M%#_K9L[2Q]3G@>WU- 'I7A;]G[P[8Z;$WB'S=0OV7,BK*R1(?1=N"<>I/X4
M9/C_ . FFQ:-/J/A,3175NI<V;N7651U"D\@_B<T 9?[/_CJXBU-O"-],SVT
MZM)9ECGRW RR#V(R?J/>@#G?BQXMU#QWX\_L#3-\EE:S_9;:!#Q++G:6/X\#
MV^IH ]-\,?L_>&['38FU_P W4;]ES(%E:.-#Z+MP3CU)Y]!0!B_$+X"V$&CS
MZGX3$L<]NI=[-W+B11UVD\@^Q)S0!4_9]\<7)O9/"-]*9(&1I;,L<E".60>Q
M'(';!]: (_VA/&%Q/JMOX1LY"((E6:Z"]7<_=4^P&#]2/2@#I_ _P'T*PTFW
MN?$MNU_J4BAGA9RL<)/\. 1DCN30!=\6_ GPQJ^G2MHEM_9>HJI,;(Y,;GL&
M4YP/<=/>@#RWX/\ B34/!?Q$;PWJ.Z.WO)C:3PL>(Y@<*P_'CW!]A0!J_'_Q
MI<7VNIX3LI6%K:A7N53_ ):2D9"GU !''J?:@#KOAW\#M(T[2X+_ ,46JWNI
M2J'-O(3Y<&>Q'\3>N>/YT =1KOP=\%:W9/ NCQ6$V/DGLQY;*?7 X/XB@#P?
MP]=ZG\(/BQ_9]W-FV\U8+G'W986QA\>H!!]N10!T?[0/BB[U#Q+:^$[1F^SV
MZI))&O\ RTF;[H/K@$8]V- '?>"/@EX=T+28GURRBU/5)%#2F8;HXS_=5>G'
MJ>M '=V7A/P_INHQW]AHUG:7<:E!)!"(SM/4''6@#8H \J_:",@^&>$^Z;R+
M?],-_7% !\ 5$?PNW(H#&[E)XZGC_"@#QCX2!+SXR:8][]\S328/_/38Q'ZT
M ?7E !0!\A:"D=E\>8HK%?W4>L2)&%/1=[#C\* '?!I$N?B_I;7/S-NF?YN[
MB-B#]<T ?7= ![4 ?(/@I1:_'2RCL^(TU21$"\_)N8?EB@"SXP_TG]H*9)V#
M*=5@0[SQMR@Q],4 ?6M !0!\E?$PQVOQTNY+7:"MW;N<?W]J$_K0!D^*-.OM
M?^+^KZ=:E1>W.IRQQ;VV#.X[>>W04 =2/@Y\3B?^/H#W_M T +_PIKXF[<_;
M%SZ?V@<T 5IO@1X_N)#+/]EEDX&Y[O)/XD4 1:PK2?M$V\5QARNJ6L; \CC8
M,?I0!]7T % !0!QGQ7T-M?\ AKK%K$I::*/[1&!U)0[L?B 1^- 'G7[.'B*-
M['5/#DKXEC?[7"">JD!6Q]"%_.@#SOQSI=_\-?BNU]:)MC6Y%[9L1\K(6SM_
M Y4__7H ^C?"GQ*\,^+-.CGM]1@MKDJ/-M9Y DD9[CGJ/<4 9/C_ .+6A>%=
M(G2POH+[5Y$(@AA<.$8]&<C@ =<=30!Y#\"/#%SKWCAO$%R"UKII,C.W\<S
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M^'-0\4Q>'=.OTO;YT9V,'S1QA1SENF?89H ^>];&/VE%_P"PS!_Z$E 'U70
M4 % "$!@00"#P0: /E?QUX>U3X2?$.'7M%#)82RF6U?'RC/WX6]L$CZ>XH ]
M>MK[P=\;_"HMIP$NXQN:'<!/:O\ WE/<>_0]^: /,=9_9S\0VUPQTC4;.\M\
M_+YI,3@>XP1^M %OP]^SCJ<MPDGB'5(+>W!RT5KEW8>FX@ ?K0![[H>A:=X;
MTB#2]*MEM[6$8"KU)[DGN3W- &=XP\%Z/XWT@V&JPG*G=%/'@21-ZJ?YCH:
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MCIVN6<4-F+=Y-RVK1G<",<D^YH \[\4:=?2?'V69+*X:+^UH3O$3$8W)SG%
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C % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
